BACKGROUND: The efficacy of bacille Calmette-Guérin (BCG) may be enhanced by heterologous vaccination strategies that boost the BCG-primed immune response. One leading booster vaccine, MVA85A (where "MVA" denotes "modified vaccinia virus Ankara"), has shown promising safety and immunogenicity in human trials performed in the United Kingdom. We investigated the safety and immunogenicity of MVA85A in mycobacteria-exposed--but Mycobacterium tuberculosis-uninfected--healthy adults from a region of South Africa where TB is endemic. METHODS: Twenty-four adults were vaccinated with MVA85A. All subjects were monitored for 1 year for adverse events and for immunological assessment. RESULTS: MVA85A vaccination was well tolerated and induced potent T cell responses, as measured by interferon (IFN)-gamma enzyme-linked immunospot assay, which exceeded prevaccination responses up to 364 days after vaccination. BCG-specific CD4+ T cells boosted by MVA85A were comprised of multiple populations expressing combinations of IFN-gamma, tumor necrosis factor (TNF)-alpha, interleukin (IL)-2, and IL-17, as measured by polychromatic flow cytometry. IFN-gamma-expressing and polyfunctional IFN-gamma+TNF-gamma+IL-2+ CD4+ T cells were boosted during the peak BCG-specific response, which occurred 7 days after vaccination. CONCLUSION: The excellent safety profile and quantitative and qualitative immunogenicity data strongly support further trials assessing the efficacy of MVA85A as a boosting vaccine in countries where TB is endemic. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00460590.
BACKGROUND: The efficacy of bacille Calmette-Guérin (BCG) may be enhanced by heterologous vaccination strategies that boost the BCG-primed immune response. One leading booster vaccine, MVA85A (where "MVA" denotes "modified vaccinia virus Ankara"), has shown promising safety and immunogenicity in human trials performed in the United Kingdom. We investigated the safety and immunogenicity of MVA85A in mycobacteria-exposed--but Mycobacterium tuberculosis-uninfected--healthy adults from a region of South Africa where TB is endemic. METHODS: Twenty-four adults were vaccinated with MVA85A. All subjects were monitored for 1 year for adverse events and for immunological assessment. RESULTS: MVA85A vaccination was well tolerated and induced potent T cell responses, as measured by interferon (IFN)-gamma enzyme-linked immunospot assay, which exceeded prevaccination responses up to 364 days after vaccination. BCG-specific CD4+ T cells boosted by MVA85A were comprised of multiple populations expressing combinations of IFN-gamma, tumor necrosis factor (TNF)-alpha, interleukin (IL)-2, and IL-17, as measured by polychromatic flow cytometry. IFN-gamma-expressing and polyfunctional IFN-gamma+TNF-gamma+IL-2+ CD4+ T cells were boosted during the peak BCG-specific response, which occurred 7 days after vaccination. CONCLUSION: The excellent safety profile and quantitative and qualitative immunogenicity data strongly support further trials assessing the efficacy of MVA85A as a boosting vaccine in countries where TB is endemic. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00460590.
Authors: Andrea M Cooper; Andre Kipnis; Joanne Turner; Jeanne Magram; Jessica Ferrante; Ian M Orme Journal: J Immunol Date: 2002-02-01 Impact factor: 5.422
Authors: Gillian F Black; Rosemary E Weir; Sian Floyd; Lyn Bliss; David K Warndorff; Amelia C Crampin; Bagrey Ngwira; Lifted Sichali; Bernadette Nazareth; Jenefer M Blackwell; Keith Branson; Steven D Chaguluka; Linda Donovan; Elizabeth Jarman; Elizabeth King; Paul E M Fine; Hazel M Dockrell Journal: Lancet Date: 2002-04-20 Impact factor: 79.321
Authors: Nilu P Goonetilleke; Helen McShane; Carolyn M Hannan; Richard J Anderson; Roger H Brookes; Adrian V S Hill Journal: J Immunol Date: 2003-08-01 Impact factor: 5.422
Authors: Samuel J McConkey; William H H Reece; Vasee S Moorthy; Daniel Webster; Susanna Dunachie; Geoff Butcher; Jenni M Vuola; Tom J Blanchard; Philip Gothard; Kate Watkins; Carolyn M Hannan; Simone Everaere; Karen Brown; Kent E Kester; James Cummings; Jackie Williams; D Gray Heppner; Ansar Pathan; Katie Flanagan; Nirmalan Arulanantham; Mark T M Roberts; Michael Roy; Geoffrey L Smith; Joerg Schneider; Tim Peto; Robert E Sinden; Sarah C Gilbert; Adrian V S Hill Journal: Nat Med Date: 2003-05-25 Impact factor: 53.440
Authors: Mushtaq Ahmed; Douglas M Smith; Tarek Hamouda; Javier Rangel-Moreno; Ali Fattom; Shabaana A Khader Journal: Vaccine Date: 2017-07-31 Impact factor: 3.641
Authors: Thomas J Scriba; Michele Tameris; Erica Smit; Linda van der Merwe; E Jane Hughes; Blessing Kadira; Katya Mauff; Sizulu Moyo; Nathaniel Brittain; Alison Lawrie; Humphrey Mulenga; Marwou de Kock; Lebohang Makhethe; Esme Janse van Rensburg; Sebastian Gelderbloem; Ashley Veldsman; Mark Hatherill; Hendrik Geldenhuys; Adrian V S Hill; Anthony Hawkridge; Gregory D Hussey; Willem A Hanekom; Helen McShane; Hassan Mahomed Journal: Am J Respir Crit Care Med Date: 2012-01-26 Impact factor: 21.405
Authors: Lin Lin; Greg Finak; Kevin Ushey; Chetan Seshadri; Thomas R Hawn; Nicole Frahm; Thomas J Scriba; Hassan Mahomed; Willem Hanekom; Pierre-Alexandre Bart; Giuseppe Pantaleo; Georgia D Tomaras; Supachai Rerks-Ngarm; Jaranit Kaewkungwal; Sorachai Nitayaphan; Punnee Pitisuttithum; Nelson L Michael; Jerome H Kim; Merlin L Robb; Robert J O'Connell; Nicos Karasavvas; Peter Gilbert; Stephen C De Rosa; M Juliana McElrath; Raphael Gottardo Journal: Nat Biotechnol Date: 2015-05-25 Impact factor: 54.908
Authors: Mark Hatherill; Hendrik Geldenhuys; Bernadette Pienaar; Sara Suliman; Phalkun Chheng; Sara M Debanne; Daniel F Hoft; W Henry Boom; Willem A Hanekom; John L Johnson Journal: Vaccine Date: 2014-05-09 Impact factor: 3.641
Authors: Thomas J Scriba; Michele Tameris; Nazma Mansoor; Erica Smit; Linda van der Merwe; Fatima Isaacs; Alana Keyser; Sizulu Moyo; Nathaniel Brittain; Alison Lawrie; Sebastian Gelderbloem; Ashley Veldsman; Mark Hatherill; Anthony Hawkridge; Adrian V S Hill; Gregory D Hussey; Hassan Mahomed; Helen McShane; Willem A Hanekom Journal: Eur J Immunol Date: 2010-01 Impact factor: 5.532